This section includes information and resources about Cancer for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos.
Boehringer Ingelheim Broadens its Breast Cancer Trial Programme for Afatinib*
New subgroup analysis of the LUX-Lung 1 trial suggests benefit from afatinib* in lung cancer patients likely to have EGFR mutations
Afatinib (BIBW 2992*) triples progression free survival in phase III study in lung cancer patients
Boehringer Ingelheim Initiates Phase III Clinical Trial with Novel Oral Agent in Advanced Breast Cancer
Boehringer Ingelheim’s lead investigational oncology compound BIBW 2992 demonstrates potential as a next generation treatment for non-small cell lung cancer and head-and-neck cancer